Top Biotech News (21 October, 2026)

Merck KGaA bets on RNAi with $1.3B Silence buyout

Summary:

Merck KGaA has agreed to buy UK RNAi specialist Silence Therapeutics for about $1.3 billion, or $20 in cash per US-listed share, a 130% premium. The deal centres on divesiran, an siRNA that produced positive Phase 2 data in the rare blood disorder polycythaemia vera. Completion is expected in the first quarter of 2027.

Roche expands Hansoh ADC partnership with over $15B in potential milestones

Summary:

Roche will pay Hansoh Pharma $400m upfront and $110m on the first anniversary, with more than $15bn in potential milestones plus royalties. The collaboration covers two preclinical ADCs and additional programmes against Roche-proposed targets. Neither the drugs nor the diseases were disclosed. It is Roche’s sixth China deal since late August.

Lilly allies with METiS in $1.1B AI nanoparticle discovery deal

Summary:

Eli Lilly has partnered with Hong Kong-listed METiS TechBio to use its AI-driven ionisable-lipid platform to design tissue-specific lipid nanoparticle delivery systems for programmes Lilly selects. METiS receives an upfront payment in the low double-digit millions of dollars, up to about $1.1 billion in milestones, and tiered single-digit royalties.

FDA approves immunotherapy that may spare rectal cancer patients chemotherapy, radiation and surgery

Summary:

The FDA granted accelerated approval to GSK’s Jemperli (dostarlimab) as the sole treatment for previously untreated stage II–III mismatch repair-deficient or MSI-high locally advanced rectal cancer. In the Phase 2 AZUR-1 trial of 154 patients, almost three-quarters needed no surgery, radiotherapy or chemotherapy after a median follow-up of more than two years.

FDA launches Rare Disease Framework Initiative

Summary:

The FDA is developing a framework to tailor evidence requirements to individual rare diseases and small patient populations while maintaining safety and effectiveness standards. Its scope spans pre-IND engagement through post-approval obligations. A public meeting is scheduled for 28 October 2026; only about 5% of rare conditions have an FDA-approved treatment.

Subscribe to the latest updates in the newsletter

Share your disease area, therapeutic candidate and research objectives.

Related Solutions

Organoid Service
Research Service
Technical Service

ODISEI CNS - Human brain & retinal organoid
solutions for translational CNS discovery.

Please provide the information below, and our team will contact you shortly with brochure and relevant case studies.

Thank you for your submission.

Our team has received your request and will get back to you shortly.
If you do not receive our confirmation email, kindly check your spam or junk folder.